Atlas Genetics, a rapid, near-patient and point-of-care (POC) testing company, announced the appointment of industry veteran Marc Jones as Chief Operating Officer (COO) and Chief Financial Officer (CFO).
In this dual role, Jones will lead Atlas Genetics’ finance and operations functions and new channel development. He will again partner with Jeffrey Luber, President and CEO of Atlas, in key areas influencing strategic direction and execution.
Luber said: “We are pleased to welcome Marc to the executive team as Atlas transitions from clinical proof of concept to its commercial phase globally,”
“The healthcare landscape is changing rapidly, with an emerging focus on consumer convenience and rapid testing in decentralised locations.”
“With the Atlas io platform’s ability to detect disease through a small, desktop instrument, we are poised to leverage these growing trends. Having talent of Marc’s calibre aboard, joining a stellar team of executives, will ensure we are ready to lead in new high-growth mobile/digital and retail health categories.”
Jones joins Atlas Genetics from Good Start Genetics, where he served as the COO and CFO.
In that role, Jones and Luber raised successive rounds of capital and helped lead the turnaround of the company to record business growth and its ultimate sale to publicly traded Invitae.
Prior to Good Start Genetics, Jones served as the CFO of T2 Biosystems, where he oversaw the company’s successful public offering, raising nearly $100 million in capital and helped drive the commercialisation of the company's first FDA approved IVD product.
Previously, Jones held the CFO position at Crashlytics, Ivenix and CHiL Semiconductor. Earlier in his career, he held a number of corporate finance positions ranging from Fortune 50 companies to high-growth startups.
